{
  "main_header": {
    "sid": 116063,
    "name": "Samrat Pharma",
    "stock_name": "Samrat Pharma",
    "full_name": "Samrat Pharmachem Ltd",
    "name_url": "stocks-analysis/samrat-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "228.10",
    "chg": -2.7,
    "chgp": "-1.17%",
    "dir": -1,
    "prev_price": "230.80",
    "mcapval": "73.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530125,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE103E01016",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "648 ",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/samrat-pharma-116063-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Samrat Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-samrat-pharma-fallingrising-3762999",
        "imagepath": "",
        "date": "2025-12-19 01:41:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Samrat Pharmachem’s share price has been under pressure for several sessions, with the stock recording losses for four consecutive days, resulting in a cumulative decline of 10.51% over this period. On 18-Dec, the stock opened with a gap down of 3.91%, signalling immediate bearish sentiment among investors. Throughout the trading day, the price touched an intraday low of ₹226, establishing a new 52-week low and underscoring the persistent weakness in the stock.</p>\n<p>The weighted average price for the day indicates that a greater volume of shares was traded closer to the lower end of the price range, suggesting that sellers dominated the session. This selling pressure is further reflected in the fact that Samrat Pharmachem is currentl..."
      },
      {
        "title": "Samrat Pharmachem Falls to 52-Week Low of Rs.230.05 Amidst Prolonged Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-falls-to-52-week-low-of-rs23005-amidst-continued-downtrend-3762234",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SamratPharmache_priceRelatedfactors_3762234.png",
        "date": "2025-12-18 09:41:01",
        "description": "Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.230.05 today, marking a significant decline amid a sustained downward trend. The stock has experienced a series of losses over the past four trading sessions, culminating in a cumulative return of -9.65% during this period, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Samrat Pharmachem Falls to 52-Week Low of Rs.237 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-falls-to-52-week-low-of-rs237-amidst-continued-downtrend-3753408",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SamratPharmache_priceRelatedfactors_3753408.png",
        "date": "2025-12-09 09:49:01",
        "description": "Samrat Pharmachem's stock price reached a fresh 52-week low of Rs.237 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced its performance over the past year."
      },
      {
        "title": "Samrat Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharma-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-outlook-3749906",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SamratPharma_mojoScore_3749906.png",
        "date": "2025-12-06 10:10:05",
        "description": "Samrat Pharma, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing operational and financial challenges. This shift highlights the company’s current standing amid a difficult market environment and evolving investor perspectives."
      },
      {
        "title": "Samrat Pharmachem Stock Falls to 52-Week Low of Rs.250",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-hits-52-week-low-amidst-continued-underperformance-3738337",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SamratPharmache_priceRelatedfactors_3738337.png",
        "date": "2025-12-01 11:08:07",
        "description": "Samrat Pharmachem's shares reached a fresh 52-week low of Rs.250 today, marking a significant decline amid broader market gains. The stock underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space."
      },
      {
        "title": "Samrat Pharmachem Stock Falls to 52-Week Low of Rs.251 Amidst Prolonged Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-hits-52-week-low-amidst-continued-underperformance-3731424",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SamratPharmache_priceRelatedfactors_3731424.png",
        "date": "2025-11-26 12:46:33",
        "description": "Samrat Pharmachem’s shares touched a fresh 52-week low of Rs.251 today, marking a significant price level amid a year of sustained underperformance relative to the broader market and sector peers."
      },
      {
        "title": "Samrat Pharmachem Falls to 52-Week Low of Rs.265 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-hits-52-week-low-amidst-continued-downtrend-3725710",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SamratPharmache_priceRelatedfactors_3725710.png",
        "date": "2025-11-24 14:36:34",
        "description": "Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.265 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year."
      },
      {
        "title": "Samrat Pharmachem Stock Falls to 52-Week Low of Rs.266.1 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-stock-falls-to-52-week-low-of-rs2661-on-20-nov-2025-3717941",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SamratPharmache_priceRelatedfactors_3717941.png",
        "date": "2025-11-20 11:12:55",
        "description": "Samrat Pharmachem has reached a new 52-week low of Rs.266.1 today, marking a significant decline in its stock price amid a broader market rally. The pharmaceutical company’s shares have slipped below all major moving averages, reflecting persistent pressures on its valuation and performance over the past year."
      },
      {
        "title": "Is Samrat Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-samrat-pharma-overvalued-or-undervalued-3713538",
        "imagepath": "",
        "date": "2025-11-19 08:07:42",
        "description": "As of 18 November 2025, the valuation grade for Samrat Pharma has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 53.48, an EV to EBITDA of 18.52, and a Price to Book Value of 1.18, all of which suggest that the stock is priced at a premium compared to its earnings and assets.\n\nIn comparison to its peers, Samrat Pharma's PE Ratio is notably higher than Sun Pharma's 36.56 and significantly exceeds Cipla's more attractive valuation at 22.49. Additionally, while the PEG Ratio stands at 0.00, indicating no growth expectations priced in, other competitors like Divi's Lab show a PEG of 1.96, reflecting a more balanced valuation. The company's recent stock performance has been poor, with a year-to-date return of -29.33%, contrasting sharply with the Sensex's gain of 8.36%, further ..."
      }
    ],
    "total": 5728,
    "sid": "116063",
    "stock_news_url": "https://www.marketsmojo.com/news/samrat-pharmachem-116063"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
      "datetime": "02-Dec-2025",
      "details": "Crisil Ltd has downgraded its rating to CrisilBB+/Negative/CrisilA4+",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "20-Nov-2025",
      "details": "Newspaper Publication - Extract of Results for the quarter and half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held Today",
      "datetime": "14-Nov-2025",
      "details": "The Board of Directors considered and took on record the Un-audited Standalone Financial Results for the quarter and half year ended September 30 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Samrat Pharmachem Ltd has declared <strong>10%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Samrat Pharma falling/rising?

2025-12-19 01:41:31

Recent Price Movement and Market Context

Samrat Pharmachem’s share price has been under pressure for several sessions, with the stock recording losses for four consecutive days, resulting in a cumulative decline of 10.51% over this period. On 18-Dec, the stock opened with a gap down of 3.91%, signalling immediate bearish sentiment among investors. Throughout the trading day, the price touched an intraday low of ₹226, establishing a new 52-week low and underscoring the persistent weakness in the stock.

The weighted average price for the day indicates that a greater volume of shares was traded closer to the lower end of the price range, suggesting that sellers dominated the session. This selling pressure is further reflected in the fact that Samrat Pharmachem is currentl...

Read More

Samrat Pharmachem Falls to 52-Week Low of Rs.230.05 Amidst Prolonged Downtrend

2025-12-18 09:41:01

Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.230.05 today, marking a significant decline amid a sustained downward trend. The stock has experienced a series of losses over the past four trading sessions, culminating in a cumulative return of -9.65% during this period, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Read More

Samrat Pharmachem Falls to 52-Week Low of Rs.237 Amidst Continued Downtrend

2025-12-09 09:49:01

Samrat Pharmachem's stock price reached a fresh 52-week low of Rs.237 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced its performance over the past year.

Read More

Samrat Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions

2025-12-06 10:10:05

Samrat Pharma, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing operational and financial challenges. This shift highlights the company’s current standing amid a difficult market environment and evolving investor perspectives.

Read More

Samrat Pharmachem Stock Falls to 52-Week Low of Rs.250

2025-12-01 11:08:07

Samrat Pharmachem's shares reached a fresh 52-week low of Rs.250 today, marking a significant decline amid broader market gains. The stock underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space.

Read More

Samrat Pharmachem Stock Falls to 52-Week Low of Rs.251 Amidst Prolonged Underperformance

2025-11-26 12:46:33

Samrat Pharmachem’s shares touched a fresh 52-week low of Rs.251 today, marking a significant price level amid a year of sustained underperformance relative to the broader market and sector peers.

Read More

Samrat Pharmachem Falls to 52-Week Low of Rs.265 Amidst Continued Downtrend

2025-11-24 14:36:34

Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.265 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Read More

Samrat Pharmachem Stock Falls to 52-Week Low of Rs.266.1 Amidst Continued Downtrend

2025-11-20 11:12:55

Samrat Pharmachem has reached a new 52-week low of Rs.266.1 today, marking a significant decline in its stock price amid a broader market rally. The pharmaceutical company’s shares have slipped below all major moving averages, reflecting persistent pressures on its valuation and performance over the past year.

Read More

Is Samrat Pharma overvalued or undervalued?

2025-11-19 08:07:42

As of 18 November 2025, the valuation grade for Samrat Pharma has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 53.48, an EV to EBITDA of 18.52, and a Price to Book Value of 1.18, all of which suggest that the stock is priced at a premium compared to its earnings and assets. In comparison to its peers, Samrat Pharma's PE Ratio is notably higher than Sun Pharma's 36.56 and significantly exceeds Cipla's more attractive valuation at 22.49. Additionally, while the PEG Ratio stands at 0.00, indicating no growth expectations priced in, other competitors like Divi's Lab show a PEG of 1.96, reflecting a more balanced valuation. The company's recent stock performance has been poor, with a year-to-date return of -29.33%, contrasting sharply with the Sensex's gain of 8.36%, further ...

Read More

View All News